Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment

Suzanne K. Swan, William Smith, Thomas C. Marbury, Mary Schumacher, Carolyn Dougherty, Bruce A. Mico, Stephen A. Villano

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The effect of renal function on the pharmacokinetics of maribavir, a novel anticytomegalovirus agent, was evaluated in 12 adults with normal renal function (creatinine clearance [CrCl] >80 mL/min) and 19 adults with renal impairment classified as mild (n = 5), moderate (n = 5), or severe (n = 9), as measured by CrCl 50-80, 30-49, and <30 mL/min, respectively. After a single oral dose of maribavir 400 mg, the pharmacokinetics of maribavir, based on total and unbound plasma concentrations, showed no statistically significant difference between subjects with normal renal function and subjects with mild/moderate or severe renal impairment. Renal impairment was associated with an increase in area under the plasma concentration-time curve (AUC) values for an inactive metabolite of maribavir, VP 44469. Results were consistent with those of previous studies, which showed that very little maribavir was excreted unchanged in urine, whereas about 22% of an oral dose of maribavir is recovered in urine as VP 44469.

Original languageEnglish (US)
Pages (from-to)209-217
Number of pages9
JournalJournal of Clinical Pharmacology
Volume47
Issue number2
DOIs
StatePublished - Feb 1 2007
Externally publishedYes

Fingerprint

Pharmacokinetics
Kidney
Creatinine
Urine
Area Under Curve
maribavir

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment. / Swan, Suzanne K.; Smith, William; Marbury, Thomas C.; Schumacher, Mary; Dougherty, Carolyn; Mico, Bruce A.; Villano, Stephen A.

In: Journal of Clinical Pharmacology, Vol. 47, No. 2, 01.02.2007, p. 209-217.

Research output: Contribution to journalArticle

Swan, Suzanne K. ; Smith, William ; Marbury, Thomas C. ; Schumacher, Mary ; Dougherty, Carolyn ; Mico, Bruce A. ; Villano, Stephen A. / Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment. In: Journal of Clinical Pharmacology. 2007 ; Vol. 47, No. 2. pp. 209-217.
@article{c77ab64b953c4e9cb8c3024cda3a878e,
title = "Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment",
abstract = "The effect of renal function on the pharmacokinetics of maribavir, a novel anticytomegalovirus agent, was evaluated in 12 adults with normal renal function (creatinine clearance [CrCl] >80 mL/min) and 19 adults with renal impairment classified as mild (n = 5), moderate (n = 5), or severe (n = 9), as measured by CrCl 50-80, 30-49, and <30 mL/min, respectively. After a single oral dose of maribavir 400 mg, the pharmacokinetics of maribavir, based on total and unbound plasma concentrations, showed no statistically significant difference between subjects with normal renal function and subjects with mild/moderate or severe renal impairment. Renal impairment was associated with an increase in area under the plasma concentration-time curve (AUC) values for an inactive metabolite of maribavir, VP 44469. Results were consistent with those of previous studies, which showed that very little maribavir was excreted unchanged in urine, whereas about 22{\%} of an oral dose of maribavir is recovered in urine as VP 44469.",
author = "Swan, {Suzanne K.} and William Smith and Marbury, {Thomas C.} and Mary Schumacher and Carolyn Dougherty and Mico, {Bruce A.} and Villano, {Stephen A.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1177/0091270006296765",
language = "English (US)",
volume = "47",
pages = "209--217",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment

AU - Swan, Suzanne K.

AU - Smith, William

AU - Marbury, Thomas C.

AU - Schumacher, Mary

AU - Dougherty, Carolyn

AU - Mico, Bruce A.

AU - Villano, Stephen A.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - The effect of renal function on the pharmacokinetics of maribavir, a novel anticytomegalovirus agent, was evaluated in 12 adults with normal renal function (creatinine clearance [CrCl] >80 mL/min) and 19 adults with renal impairment classified as mild (n = 5), moderate (n = 5), or severe (n = 9), as measured by CrCl 50-80, 30-49, and <30 mL/min, respectively. After a single oral dose of maribavir 400 mg, the pharmacokinetics of maribavir, based on total and unbound plasma concentrations, showed no statistically significant difference between subjects with normal renal function and subjects with mild/moderate or severe renal impairment. Renal impairment was associated with an increase in area under the plasma concentration-time curve (AUC) values for an inactive metabolite of maribavir, VP 44469. Results were consistent with those of previous studies, which showed that very little maribavir was excreted unchanged in urine, whereas about 22% of an oral dose of maribavir is recovered in urine as VP 44469.

AB - The effect of renal function on the pharmacokinetics of maribavir, a novel anticytomegalovirus agent, was evaluated in 12 adults with normal renal function (creatinine clearance [CrCl] >80 mL/min) and 19 adults with renal impairment classified as mild (n = 5), moderate (n = 5), or severe (n = 9), as measured by CrCl 50-80, 30-49, and <30 mL/min, respectively. After a single oral dose of maribavir 400 mg, the pharmacokinetics of maribavir, based on total and unbound plasma concentrations, showed no statistically significant difference between subjects with normal renal function and subjects with mild/moderate or severe renal impairment. Renal impairment was associated with an increase in area under the plasma concentration-time curve (AUC) values for an inactive metabolite of maribavir, VP 44469. Results were consistent with those of previous studies, which showed that very little maribavir was excreted unchanged in urine, whereas about 22% of an oral dose of maribavir is recovered in urine as VP 44469.

UR - http://www.scopus.com/inward/record.url?scp=33846408272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846408272&partnerID=8YFLogxK

U2 - 10.1177/0091270006296765

DO - 10.1177/0091270006296765

M3 - Article

VL - 47

SP - 209

EP - 217

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 2

ER -